The Effect of Enteral Nutrition Supplemented With Prebiotics on Colonic Microbiota in the Critically Ill Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary objective of this study is to measure the change of concentration of faecal bifidobacteria between critically ill patients who receive enteral formula with and without prebiotics during enteral nutrition.Our null hypothesis is that there is no difference in the concentration of faecal bifidobacteria between critically ill patients who receive enteral formula with and without prebiotics during enteral nutrition (EN). Three faecal samples will be taken from the patient. First faecal sample is the first stool after initiation of EN and second sample is taken seven days after the initial sample and the third faecal sample is taken at day 14 after initial sample. Patient will be randomized to receive either of described formula after baseline (first) stool sample is obtained. Patient will be monitored up to 14 days after the initial stool sample is obtained.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Probiotics in Enteral Feeding in Critically Ill Patients

NCT01792401

Critical Illness Dietary Modification Probiotics +2 more

COMPLETED PHASE2

The Effect of Prophylactic Probiotic Lactobacilli in Enteral Feeding on Nosocomial Pneumonia Rates in Critically Ill Patients

NCT00256087

Critical Illness

COMPLETED NA

Probiotic Enteral Administration in Mechanically Ventilated Patients

NCT00122408

Pneumonia

TERMINATED PHASE1

Probiotics For The Prevention of Antibiotics Associated Diarrhea in the Pediatric Intensive Care Unit

NCT06109740

Critical Illness Antibiotic-associated Diarrhea

COMPLETED NA

The Effect of Feeding Infant Formula Containing Prebiotics and/or Probiotics

NCT02948114

Metabolomics

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Written approval of the study has been obtained from the University Malaya Medical Centre (UMMC) Ethics Committee before commencement of this study

Patients will be screened for inclusion and exclusion criteria of the study and consent will be obtained from the patients or their legal representative in view of most critically ill patients are unconscious. Patients or their legal representative will be briefed regarding the objectives and the design of the study.

Critically ill patients recruited for this study will be exclusively on EN as clinically indicated. The volume of formula prescribed is based on each patient's total energy expenditure, which will be calculated by clinical dietitians. Formula will be delivered through a Ryles tube according to dietitians' order.

A faecal sample from the recruited patients will be collected for analysis at baseline, the first stool output after initiation of EN. Once baseline sample is collected, patients will be randomly assigned to receive enteral formula with or without prebiotics. Randomisation will be generated by using the website Randomization.com (http://www.randomization.com). Patients will be monitored for at least 14 days from passage of the first faecal sample after initiation of EN.

A faecal sample will be collected for analysis on days 0, 7, and 14. If there is absence of habitual or meal cues to stool output, samples will be collected and analyzed from each patient during 3 days periods at Day 6-8 for second faecal sample and Day 12-14 for the third faecal sample.

To guarantee accurate measurement of microbiota and shirt chain fatty acids (SCFA), only fresh faecal samples will be analyzed.Faecal samples will be collected within 1 hour of voiding and will immediately be transported to the laboratory for analysis of microbiota. The faecal sample will be homogenized using a sterile stainless steel Waring blender and aliquots of each specimen and will be frozen at -80°C until DNA is extracted.

Although the study is an open-label study, the researcher will be blinded for the analysis of the faecal sample for the quantification of faecal microbiota and short SCFA. An external Predominant component of the faecal microbiota; Bacteroides, Bifidobacteria, Clostridia and Lactobacilli will be quantified using Real Time Polymerase Chain Reaction (PCR). Faecal SCFA will be analyzed using gas-liquid chromatography, and C.difficile-enterotoxins A and B will be measured using enzyme-linked immunosorbent assay kit.

Faecal output will be recorded by nursing staff using a stool chart validated for use in this patient group. The chart will aid in the characterization of faecal frequency, consistency, and weight, which are then summarized into a daily stool score. A score of 15 or more is used to indicate diarrhoea (Whelan, Judd, Preedy, \& Taylor, 2008). Patients will be visited once, daily during weekdays and contacted by telephone during weekends to monitor data recording by the nursing staff.

Details of EN regimen; formula used, amount, frequency, route and mode of delivery will be recorded progressively. Demographic data such as age sex, race and clinical details such as antibiotic, medications prescription and patients' progression will be extracted from the patients' medical notes daily.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diarrhoea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

prebiotics-free enteral formula

Patients in this arm will be receiving standard, prebiotics-free enteral formula : Osmolite 1 cal

Group Type ACTIVE_COMPARATOR

Prebiotics-free enteral formula

Intervention Type DIETARY_SUPPLEMENT

Patient will be given Osmolite 1 cal for 2 weeks after baseline stool sample obtained

prebiotics containing enteral formula

Patients in this arm will be receiving prebiotics containing enteral formula:Ensure Fos for 14 days

Group Type EXPERIMENTAL

Prebiotics containing enteral formula

Intervention Type DIETARY_SUPPLEMENT

Patient will be given Ensure Fos for 2 weeks after baseline stool sample obtained

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Prebiotics-free enteral formula

Patient will be given Osmolite 1 cal for 2 weeks after baseline stool sample obtained

Intervention Type DIETARY_SUPPLEMENT

Prebiotics containing enteral formula

Patient will be given Ensure Fos for 2 weeks after baseline stool sample obtained

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Osmolite 1 cal Ensure Fos

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients receiving exclusive EN , nasogastric, continuous infusion
* Adult patients , 18 years old and above
* Critically ill patients
* Expected to require EN more than five days(Bleichner et al., 1997)

Exclusion Criteria

* Patients with gastrointestinal disease (Sokol et al., 2006) or GIT surgery
* Patients receiving lactulose (Bouhnik et al., 2004)
* Currently under chemotherapy treatment (Kapkac et al., 2003)
* Patients who had received prebiotics and probiotics supplements within the previous one month
* Patients who have diarrhoea, 3 consecutive days (Majid et al, 2013)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No